Zika virus (ZIKV) recently dispersed throughout the tropics and sub-tropics causing epidemics 12 associated with congenital disease and neurological complications. There is currently no 13 commercial vaccine for ZIKV. Here we describe the initial development of a chimeric virus 14 containing the prM/E proteins of a ZIKV epidemic strain incorporated into a yellow fever 17-15 D attenuated backbone. Using the versatile and rapid ISA (Infectious Subgenomic Amplicons) 16 reverse genetics method, we compared different constructs and confirmed the need to modify 17 the cleavage site between the pre-peptide and prM protein. Genotypic characterization of the 18 chimeras indicates that emergence of compensatory mutations in the E protein is required to 19 restore virus replicative fitness. Using an immunocompromised mouse model, we demonstrate 20 that mice infected with the chimeric virus produced levels of neutralizing antibodies close to 21 those observed following infection with ZIKV and that pre-immunized mice were protected 22 against viscerotropic and neuroinvasive virus following challenge with a heterologous strain of 23 ZIKV. These data provide a sound basis for the future development of this ZIKV vaccine 24 candidate. 25
Introduction

26
Zika virus (ZIKV; family Flaviviridae, genus Flavivirus) is a single-stranded positive-sense 27 enveloped RNA virus. Its genome of 10.8 kb encodes a single polyprotein which is processed 28 into three structural proteins (C, PrM and E), and seven nonstructural proteins (NS1, NS2A, 29 NS2B, NS3, NS4A, NS4B and NS5) by viral and host proteases 1 . Phylogenetic studies showed 30 that all ZIKV strains characterized so far belonged among two distinct lineages (African and 31 Asian) based on the initial geographic distribution of this virus 2 . ZIKV is a mosquito-borne 32 flavivirus transmitted primarily by Aedes spp. mosquitoes 3 . 33
Long considered to cause mild disease in humans, this arbovirus remained relatively unstudied 34 until 2007, when it provoked a large outbreak in Micronesia 4 . Subsequently, several outbreaks 35 occurred in different Pacific Ocean islands including French Polynesia in 2013, where it was 36 associated with an increase of Guillain-Barré syndrome 5 . ZIKV then spread to the American 37 continent causing major outbreaks in Central/South America and the Caribbean and was linked 38
with an increase of congenital neurological complications. Sexual transmission of ZIKV was 39 also reported 6 . There is currently no commercial antiviral drug or vaccine for this virus 7 . 40
Several approaches are now available with which to develop inactivated 8 and recombinant 41 (DNA-9 or RNA-based 10 ) ZIKV vaccines. However, live attenuated vaccines have several 42 advantages including reduced costs and single dose induction of long-term immunity 11 . Several 43 groups developed live ZIKV vaccine candidates by deletions in the 3' untranslated region of 44 the viral genome 12, 13 . More recently, a chimeric ZIKV vaccine candidate based on the Japanese 45 encephalitis virus live-attenuated train SA14-14-2 was reported 14 . The chimeric approach had 46 been used since the late 1990s to develop vaccine candidates against several health-threatening 47 flaviviruses including West-Nile virus, Japanese encephalitis virus and all serotypes of the 48 dengue virus [15] [16] [17] . This approach consists of incorporating prM/E of a pathogenic flavivirus in 49 a backbone of a licensed live-attenuated vaccine strain. Indeed, E protein is prominently 50 exposed at the surface of viral particles and is de facto the major determinant of viral 51 antigenicity 1 . In almost all cases, the well-characterized live attenuated 17-D strain used to 52 prevent yellow fever virus (YFV) infections has been used as the genetic backbone. Some of 53 these live-attenuated vaccines are currently commercially available 18, 19 . 54
Here we describe the development of a chimeric virus harboring the prM/E of an epidemic 55 ZIKV (H/PF/2013) strain and the 17-D vaccine strain as the genetic backbone. The user-56 friendly and rapid ISA (Infectious Subgenomic Amplicons) reverse genetics method was used 57
to generate this chimeric virus 20 . Finally, in cellulo and in vivo characterization of this strain 58 demonstrated its potential to become a live-attenuated vaccine candidate. 59
Results
61
Design and rescue of chimeric viruses 62
The chimeric viruses were constructed using the yellow fever 17-D vaccine strain as a genetic 63 backbone and by replacing the prM/E of this vaccine strain by those of the Asian ZIKV PF 64 epidemic strains. Three different constructs, designated A, B and C, were constructed using 65 variable sites flanking ZIKV prM/E coding sequences ( Fig.1 ). Construct A harbored the pre-66 peptide and cleavage site before prM from the 17-D vaccine strain. Construct B harbored the 67 pre-peptide from the 17-D vaccine strain and cleavage site before prM from ZIKV. Construct 68 C harbored the pre-peptide and cleavage site before the prM from ZIKV. They all contained 69 the cleavage site of the 17-D vaccine strain between E and NS1 proteins. 70
The ISA procedure was used to rescue the viruses: Three overlapping amplicons that contain 71 the complete genome flanked at its 5' and 3' extremities respectively by the human 72 cytomegalovirus promoter (pCMV) and the hepatitis delta ribozyme followed by the simian 73 virus 40 polyadenylation signal (HDR/SV40pA) were transfected into a mix of HEK-74 293/BHK21 cells. Because the first amplicon contains the entire structural coding region, it was 75 only necessary to exchange the first amplicon of our already functional yellow fever 17-D 76 vaccine strain reverse genetic system to attempt replicative virus production. 77
For each construct, we performed two independent cell transfection experiments of five 78
replicates. After an incubation of six days, cell supernatant media were passaged four times in 79
Vero-E6 cells. Virus replication was assessed in cell supernatant medium at the last passage 80 (called passage #4) using a real-time quantitative RT-PCR assay. No viral replication was 81 detected for constructs A and B. In contrast, we detected, with construct C, virus replication in 82 one well (1/5) in both independent transfection experiments. These results highlighted the fact 83 that the choice of the nature of the pre-peptide and cleavage site between the capsid and prM 84 proteins is a crucial parameter when designing chimeric flaviviruses. During the first cell 85 transfection experiment, we obtained at passage #4 high amounts of viral genome copies (1.78 86 e+9 viral RNA copies/mL). This virus was designated CH-17-D/ZIKV and used for in cellulo 87 and in vivo characterizations. Surprisingly, during the second experiment, we detected very low 88
quantities of viral genome at passage #4 (3.57 e+3 viral RNA copies/mL). This virus was 89 designated CH-17-D/ZIKV*. We then performed four additional passages using the same 90 procedure. Quantities of viral genomes in cell supernatants media were assessed from passage 91 #1 to #8 and compared with that of CH-17-D/ZIKV (Fig. 2 ). We found that amounts of viral 92 genomes for CH-17-D/ZIKV reached a plateau at passage #2. In contrast, we observed an 93 increase in the production of CH-17-D/ZIKV* from passage #6 to passage #8 where amounts 94 of viral genome reached values similar to those observed with CH-17-D/ZIKV (2,67e+9 viral 95 RNA copies/mL) ( Fig. 2) . 96
CH-17-D/ZIKV genotypic characterization 97
In order to find the genotypic determinants associated with the difference of viral replication 98 observed between CH-17-D/ZIKV and CH-17-D/ZIKV*, the complete genome of CH-17-99 D/ZIKV was obtained at passage #2 and #4 and compared with the sequence of the original 100 construct. Only five substitutions were detected at passage #2 of which two were non-101 synonymous confirming the genome integrity of this strain ( Table 1) . Four of them were already 102 fixed or almost fixed. At passage #4, all these mutations were fixed and no additional mutations 103 were found. Interestingly, both non-synonymous mutations are located in domain II of E 104 protein, respectively at residues E255 and E285 21 . Consequently, we determined the sequence 105 of the 5' region of the viral genome of CH-17-D/ZIKV* (until NS1 coding region) at passage 106 #4 and the complete genome sequence of CH-17-D/ZIKV* at passage #8 ( Table 1) . While only 107 one transitory substitution was detected at passage #4, all the mutations found with CH-17-108 D/ZIKV were detected at passage #8 including the two non-synonymous mutations located in 109 E coding region. This high level of parallel evolution associated with the chronology of events 110 strongly suggests that these five mutations are associated with the increase of replicative fitness 111 observed with both viruses. 112
CH-17-D/ZIKV initial characterization 113
To confirm the presence of the ZIKV E protein in Vero-E6 cells infected by the chimeric virus, 114
we performed an indirect immunofluorescence assay using a specific ZIKV immune serum as 115 the primary antibody ( Fig. 3A) . ZIKV PF and the 17-D vaccine strains were used as positive 116 and negative controls. As expected, no fluorescence was observed with the 17-D vaccine strain 117 and positive cells were observed at day 2 and 5 post-infection with both chimeric and ZIKV 118 strains confirming that the ZIKV E protein is expressed in infected cells. At day 2 post-119 infection, the number of positive cells with ZIKV is higher than with CH-17-D/ZIKV in 120 agreement with growth replication kinetics in VeroE6 cells. Since a cytopathic effect was 121 observed with the ZIKV strain at day 5, the number of positive cells was lower with this virus. 122
Viability assays in Vero-E6 cells confirmed this observation: the CH-17-D/ZIKV virus is less 123 cytopathic (mean value: 73% of cell viability) at day 5 post-infection than the ZIKV (mean 124 value: 49% of cell viability) (Supplemental Fig. 1 ). We then performed comparative growth 125 kinetics of these viruses in three different cell lines (HUH7.5, HEK-293 and Vero-E6). Cell 126 supernatant media were harvested at different time points after infection to assess the amount 127 of viral RNA (Fig. 3B , 3C and 3D). Similar growth kinetics curves were observed for all viruses 128 in HUH7.5. In Vero-E6 cells, higher amounts of viral genome were not found in cell 129 supernatants until day 5 post-infection with the chimeric virus. In HEK-293 cells, the chimeric 130 virus had similar behavior to that of the 17-D vaccine strain. 131
CH-17-D/ZIKV characterization in Vero cells
Since Vero cells are widely used for vaccine production 22 , we characterized CH-17-D/ZIKV in 134 this cell line. Because CH-17-D/ZIKV is already adapted at passage #4 (see above), we used 135 cell supernatant from this passage to perform growth kinetics in Vero cells. Cell supernatant 136 media were harvested at different time points after infection to assess infectious titers (TCID50 137 assay) and the amount of viral RNA ( Fig. 3E/F ). The results showed that these cells enabled 138 the production of highly infectious viral particle at day 6 post-infection. We also studied the 139 genetic stability of CH-17-D/ZIKV by performing 6 additional passages in Vero cells and the 140 complete genome sequence was obtained at passage #8 and #10 (Table 1 ). Our findings 141 revealed remarkable genetic stability since all mutations at passage #4 remained stable and no 142 additional mutation was detected. 143
CH-17-D/ZIKV in vivo characterization 144
Because ZIKV and 17-D vaccine strain do not replicate in immunocompetent mice, we used 145 immunocompromised mice as model to study the chimeric virus in vivo. Each time animals 146 were immunized or infected, they were transiently immunocompromised following a two-step 147 inoculation of anti-IFNAR antibody 23-25 as described in the Methods section. 148
Six groups of four mice were inoculated with two different dosages of CH-17-D/ZIKV, 149 ZIKV,17-D vaccine strain to assess antibody production ( Fig. 4A ). A control group (mock) of 150 four mice were inoculated with PBS. Twenty-one days after immunization, mice were 151 sacrificed and their sera were tested for the presence of antibodies to ZIKV and YFV ( Fig.4B  152 and 4C) using a viral RNA Yield Reduction Neutralization Test (YRNT; see Methods). As a 153 result, we demonstrated that immunization with the chimeric virus induced production of 154 neutralizing antibodies against ZIKV confirming the starting hypothesis of this study. We 155 detected a slightly higher level of neutralizing antibodies when mice were infected with ZIKV. 156
In all cases, both dosages used induced comparable neutralizing titers. Consistently with 157 previous studies, mice immunized with the 17-D vaccine strain did not produce antibodies 158 against ZIKV. Indeed, based on the amino acid sequence divergence of antigenic proteins, it is 159 well established that no cross-neutralizing activity exists between these two distant 160 flaviviruses 26 . As expected, mice immunized with the 17-D vaccine strain produced high levels 161
of neutralizing antibodies against YFV while those infected with ZIKV did not produce any 162 antibodies against YFV. Interestingly, immunization with CH-17-D/ZIKV induced production 163 of neutralizing antibodies against YFV. This result demonstrated the immunogenicity of the 164 viral proteins encoded by the 17-D vaccine strain backbone. We also attempted to isolate 165 chimeric virus from animal blood samples to assess the ability of the chimeric virus to replicate 166 in vivo. At day 2 and 3 post immunization, to avoid the possibility of isolating residual virus 167 from the immunization, we collected a blood drop from the mice tail and found two positive 168 samples (one at each day) (Supplemental Fig. 2 ). These findings suggest that CH-17-D/ZIKV is able to replicate in mice since comparable neutralizing titers were measured with all mice 170 immunized. 171
In another experiment, we assessed protection against subsequent infection by wild-type ZIKV 172
following immunization with CH-17-D/ZIKV or 17-D vaccine strain ( Fig. 5A ). Groups of mice 173 were immunized with two dosages of CH-17-D/ZIKV and 17-D vaccine strain twenty-one days 174
prior to challenge with a ZIKV African strain (Dak84). Three control groups were also used: 175 one immunized with PBS and then challenged (named unvaccinated group), one immunized 176
with ZIKV PF and then challenged (named ZIKV PF group) and one immunized and challenged 177 with PBS (mock). Since 100% of the mice of the control group ZIKV PF were viremic at day 178 2 and 3 post-challenge, this criterion was not used to assess protection (Supplemental Fig. 3  179 and Supplemental Table 1 ). Thereby, the protection was evaluated by determining the 180 proportion of mice with organs (brain and spleen) positive for the presence of ZIKV at day 10 181 post-challenge. We observed that 10% of the spleens and brains from mice immunized with the 182 chimeric virus (both groups) were positive (Table 2 ). In contrast, respectively 100% and 87.5% 183 of the spleens and brains from mice immunized with the 17-D vaccine strain (both groups) were 184 positive (p value = 0.0004 for spleens and 0.0029 for brains; Fisher exact test). As expected 185 100% and 0% of the organs respectively from mice of the unvaccinated group and from the 186 ZIKV PF group were positive. Viral RNA yields found in the organs were quite variable in all 187 positive samples (Fig. 5B) Interestingly, mutations located in this particular domain of the E protein were previously 207 described in cellulo with 17-D vaccine strain based chimeric flaviviruses (DENV type 1/2 and 208 Japanese encephalitis virus) 29,30 . These findings suggest that emergence of compensatory 209 mutations in the E protein is probably necessary to restore the replicative fitness of the virus 210 following exchange of two of its structural proteins. 211
By comparing the growth properties of our chimeric virus with its two parental strains in 212 different mammalian cells, we found that this new synthetic virus had its own biological 213
properties probably in relation to the nature of this new association of viral proteins. In fact, we 214 observed than this strain is fitter than parental strains in Vero-E6 cells and close to 17-D vaccine 215 strain in HEK-293 cells. 216
Genetic stability is a major concern when designing future live-attenuated vaccine candidates. 217
Using Vero cells, widely used for vaccine production 22 and the adapted chimeric virus, we 218
performed serial passages to assess this essential criterion. We demonstrated that once initial 219 adaptation was achieved, the chimeric virus remained genetically stable. 220
We used transitory immunocompromised mice as an animal model system to characterize in 221 vivo the chimeric virus. We demonstrated that mice infected with this virus produced levels of 222 neutralizing antibodies close to those observed following infection by ZIKV. Our results also 223 showed that immunization using the chimeric strain significantly protected mice against brain 224 and spleen invasion induced by a heterologous strain of ZIKV. Altogether, these results provide 225 evidence that this chimeric strain had all the prerequisites to be tested in a more relevant animal 226 model such as the microcephalic sensitive mouse model 31 . 227
The strategy used in the present study to develop a live ZIKV vaccine candidate has several 228 advantages: the 17-D vaccine strain has long history of use in hundreds of millions of persons 32 229 and is considered as the safest live-attenuated vaccine 33 . Moreover, in comparison with targeted 230 attenuation strategies such as local modification of genomic region, our approach eliminates 231 the risk of phenotype reversion by potential homologous recombination. Finally, although 232 potential occurrence of antibody dependent enhancement phenomenon consecutive has to be 233 considered with chimeric vaccine, there is currently no epidemiological data supporting this 234 hypothesis in area where several flaviruses co-circulate 34 . 235
In conclusion, our data provide sound basis for the future development of this vaccine 236
candidate. Furthermore, the approach used in this study to rescue the chimeric virus showed 237 that significant advances in the development of reverse genetics methods now offer the 238 possibility of drastically reducing the timeframe between the emergence of a novel viral 239 pathogen and the availability of a live-attenuated vaccine candidate. Subgenomic Amplicons) reverse genetics method as previously described 20,27,36 . 278
Preparation of subgenomic DNA fragments 279
The complete viral genome was amplified by PCR as three overlapping DNA fragments. The 280 first and last fragments were flanked respectively by the 5' and 3' termini and included the 281 human cytomegalovirus promoter (pCMV) and the hepatitis delta ribozyme followed by the 282 simian virus 40 polyadenylation signal (HDR/SV40pA). We started by using a reverse genetics 283 system designed for the YFV 17-D strain (available on supplemental material). Because the 284 first DNA fragment contained all regions encoding structural genes, only this fragment was 285 modified to design chimeric viruses (the primers are listed in supplemental table 3). 286 DNA fragments were generated by PCR using de novo synthesized genes (Genscript) as 287
templates. The sequence of the primers used is listed in supplemental table 2. PCR mixes were 288 prepared using the Platinum PCR SuperMix High Fidelity kit (Life Technologies) following 289 the manufacturer's instructions. Amplifications were performed using ABI 2720 thermal cycler 290 (Applied Biosytems) with the following conditions: 94°C for 2 min followed by 40 cycles of 291 94°C for 15 s, 60°C for 30 s, 68°C for 5 min plus 10 min final elongation at 68°C. PCR product 292 size and quality were controlled by running gel electrophoresis and DNA fragments were 293 purified using the High pure PCR product purification kit (Roche). 294
Cell transfection 295
Mixtures of BHK-21 and HEK-293 cells were seeded into PureCoat amine 6-well cell culture 296
plates (Corning) one-day prior to transfection. Cells were transfected with 2µg of an equimolar 297 mix of the three DNA fragments using lipofectamine 3000 (Life Technologies) and following 298 the manufacturer's instructions. Each transfection was performed in 5 replicates. After 24h of 299 incubation, the cell supernatant media were removed and replaced by fresh cell culture medium. PCR System (Applied Biosytems) with the following conditions: 10 min at 50°C, 2 min at 320 95°C, and 40 amplification cycles (95°C for 3 sec followed by 30sec at 60°C). Amounts of viral 321 RNA were calculated from standard curves (quantified T7-generated synthetic RNA standards 322 were used). 323 324
Complete Genome sequencing 325
Complete and partial genome sequencing of chimeric virus were performed as previously 326 described 37 . Viral RNA extraction was performed as described above. A set of specific primer 327 pairs (supplemental the CLC Genomics Workbench 6 software (CLC Bio). They were trimmed using quality score, 332 by removing the primer sequences at their termini and by finally systematically removing 20 nt 333 at the 5′ and 3′ termini. Remaining reads with a length greater than 99 were mapped using the 334 designed sequence of the chimeric virus as reference to obtain a consensus sequence. Mutation 335 frequency for each position was calculated as the number of mutated reads divided by the total 336 number of reads at that site. 337
Tissue culture infectious dose 50 (TCID50) assay 338 96-well cell culture plate of confluent Vero-E6 containing 100µL/well of media was inoculated 339 (50µL/well) with 10-fold serial dilutions of centrifugation clarified cell culture supernatant 340 medium. Each dilution was repeated 6 times. The plate was incubated for 7 days and read for 341 absence or presence of CPE in each well. TCID50 titers were then calculated using the Muench method 38 with HBSS and fixed with 4% paraformaldehyde for 2 hours. Detection of viral antigens was 359 performed as previously described 20,39 using a specific ZIKV immune serum as the primary 360 antibody (dilution: 1/50) collected from a Syrian Hamster immunized with the ZIKV strain 361
Mart2015 (see below). This serum was shown to neutralize more than 90 % of ZIKV PF 362 replication until 1/3000 dilution (data not shown). The secondary antibody used was a Goat 363 anti-hamster Alexa 488 antibody (Invitrogen) at 1/500 dilution. Slides were observed using a 364
Eurostar II fluorescence microscope with the Europicture software (Euroimmune). 365 366
Viral RNA Yield Reduction Neutralization Test (YRNT) 367
Vero-E6 cells were seeded into a 96-well cell culture plate one day prior to infection (5×10 4 368 cells in 100µL of medium containing 2.5% FBS per well). The next day, two fold serial 369 dilutions of sera (from 1/20 to 2560; diluted with medium containing 2.5% FBS) were mixed 370 (50:50; v/v) with appropriate amounts of viral stock (diluted in medium containing 2.5% FBS), 371 incubated 1h 30 min. at 37°C/5%CO2 and then added to cells (50µL/well). The amount of virus 372 added had been calibrated to ensure that virus production in cell supernatant medium did not 373 reach a plateau at the readout time 40 . Cells were incubated for 3 days and 100µL of cell 374 supernatant medium was harvested to perform nucleic acid extraction and to quantify amounts 375 of viral RNA using a real-time qRT-PCR assay (see above). Each serum dilution was tested in 376 triplicate and duplicate for the control group. For each experiment, a virus replication control 377 (VC) was performed in quadruplicate to asses viral replication. For each serum dilution, viral 378
RNA yield reduction (% of viral inhibition) was calculated using as reference the mean amount 379 of viral RNA obtained with VC. 50% and 90% viral inhibition cut-offs were used to estimate 380 'viral RNA Yield Reduction Neutralization 50% and 90% (YRNT50 ; YRNT90) titers using 381 the method of Reed and Muench 38 . Golden hamster immunization 396
One 4-weeks-old female Syrian Hamster (Janvier) was intra-peritoneally immunized with 397 100μL containing 10 5 TCID50 of ZIKV strain Mart2015. 21 days later the Hamster was re-398 injected with the same dose. The hamster did not show any sign of illness or weight loss. 15 399 days later, the hamster was euthanized and a blood sample (intracardiac puncture) was 400 collected. After centrifugation, serum was stored at -80°C. 401
Administration of anti-IFNAR antibody 402
All the mice used were immunocompromised following a two-step inoculation of anti-IFNAR 403 antibody (clone MAR1-5A3; Interchim; intraperitoneal injection ; 120µL) 23,25 : 1mg one day prior and 1 mg one day after each infection/immunization (i.e. the mice challenged were 405 immunocompromised twice with this two-step procedure). 406
Mice immunization 407
Six groups of four 3-weeks-old female C57/bl6 mice (Charles River) were intraperitoneally 408 inoculated with 100µL of virus: two groups were immunized with the YFV 17-D strain (two 409 dosages: 10 4 and 10 5 TCID50), two groups were immunized with the ZIKV PF strain (two 410 dosages: 10 5 and 10 6 TCID50) and two groups were immunized with the CH-17-D/ZIKV strain 411 (two dosages: 10 4 and 10 5 TCID50). A control group of four mice was used as negative control 412 group (non-immunized mice). 413
Blood collection (10µL) from the tail vein was performed at days 2 and 3 post-immunization 414 to detect infectious virus by cell culture isolation. Immediately after its collection, all the blood 415 was inoculated into a 12-well cell culture plate containing confluent Vero-E6 cells and 150µL 416 of medium/well. After an incubation of 2 hours, 100µL of the inoculum was harvested. The 417 cells were washed (HBSS), 1.5mL/well of fresh medium was added to the cells which were 418 incubated for 6 days. Finally, 100µL of cell supernatant medium was harvested to perform 419 nucleic acid extraction and to quantify amounts of viral RNA using a real-time qRT-PCR assay 420
as described above. 421
At day 21 post-infection, all animals were euthanized. Blood samples were then collected 422 (intracardiac puncture) from euthanized animals. After blood centrifugation, sera were stored 423 at -80°C before being used to perform the neutralization tests. 424
Challenge experiments 425
Five groups of four 3-weeks-old female C57/bl6 mice (Charles River) were intraperitoneally 426 inoculated with 100µL of virus: two groups were immunized with the YFV 17-D strain (two 427 dosages: 10 4 and 10 5 TCID50), two groups were immunized with the CH-17-D/ZIKV strain 428 (two dosages: 10 4 and 10 5 TCID50), and one group was immunized mice with the ZIKV PF 429 strain (10 5 TCID50). Two control groups of 4 mice were used to perform (i) mock control group 430
(non-immunized/non-challenged mice); and (ii) negative control group (non-immunized mice; 431 challenged. 432
All animals (except mock control group) were then challenged with 10 6 TCID50 of ZIKV 433
Dak84. Blood collection (10µL) from the tail vein was performed at days 2 and 3 post-challenge 434 to assess viremia by qRT-PCR. At day 10 post-challenge, all the animals were euthanized. 435
Organs (spleen and brain) were then collected in 1 mL of HBSS supplemented with 10% of 436 FBS and crushed 10 minutes at 30 cycles per second with one bead of tungsten using the Tissue 437
Lyser machine (Retsch MM400). After centrifugation at 5000g during 10 min, the supernatant 438 medium was collected centrifuged again at 10,000g for 10 min. 50 µL of the supernatant 439 medium was used to perform nucleic acid extraction and to quantify amounts of viral RNA 440 using a real-time qRT-PCR assay (see above). 441
Statistical analysis 442
All data obtained were analyzed using Graph pad prism 7 software (Graph pad software Groups of mice were immunized with two doses (10e4 and 10e5 TCID50) of CH-17-D/ZIKV, 614 the 17-D vaccine strain or PBS (unvaccinated). Twenty-one days later, mice were challenged 615 with 10e6 TCID50 of a ZIKV African strain. The proportion of mice with positive spleen/brain 616 at day 10 post-challenge was expressed as percentage. Results from both doses of viruses are 617 pooled (results for each group are in supplemental Table 2) 
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